Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo

Journal of Neurochemistry

Volumn 108, Issue 4, 2009, Pages 1097-1108

  Hong, Hyun Seok ^b   Rana, Sandeep ^a   Barrigan, Lydia ^a   Shi, Aibin ^a   Zhang, Yi ^c   Zhou, Feimeng ^c   Jin, Lee Way ^b   Hua, Duy H ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

5x familial Alzheimer's disease mice; Anti amyloid effect; Atomic force microscopy; Disaggregation of A oligomers and protofibrils; Inhibition of A fibrillation; Tricyclic pyrone CP2

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CONGO RED; CP 2; CURCUMIN; NEUROPROTECTIVE AGENT; PYRONE DERIVATIVE; UNCLASSIFIED DRUG;

ALPHA HELIX; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; BRAIN TOXICITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; EXPERIMENTAL MODEL; FAMILIAL DISEASE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BRAIN; DISEASE MODELS, ANIMAL; DOWN-REGULATION; MACROMOLECULAR SUBSTANCES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; NEUROFIBRILS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; POLYMERS; PROTEIN STRUCTURE, SECONDARY; PYRONES; SENILE PLAQUES; TREATMENT OUTCOME;

ANIMALIA; MUS;

EID: 58549104760     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05866.x     Document Type: Article

References (57)

1. Adessi C., Frossard M.-J., Boissard C. et al. (2003) Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem. 278, 13905 13911.
2. Adlard P. A., Cherny R. A., Finkelstein D. A. et al. (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59, 43 55.
3. Bales K. R. (2007) Paroxetine administration decreases AD-like pathology and reverses memory impairments in a transgenic model of Alzheimer disease. Exp. Neurol. 207, 1 3.
4. Bartolini M., Bertucci C., Bolognesi M. L., Caballi A., Melchiorre C. Andrisano V. (2007) Insight into the kinetic of amyloid β (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. ChemBioChem 8, 2152 2161.
5. Begum A. N., Jones M. R., Lim G. P. et al. (2008) Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J. Pharm. Exp. Ther. 326, 196 208.
6. Blanchard B. J., Chen A., Roseboom L. M., Stafford K. A., Weigele P. Ingram V. M. (2004) Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc. Natl Acad. Sci. USA 101, 14326 14332.
7. Cao C., Lin X., Wahi M. M., Jackson E. A. Potter H. Jr. (2008) Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid β peptides. BMC Neurosci. 9, art. no. 25 http://www.biomedcentral.com/content/pdf/1471-2202- 9-25.pdf.
8. Chan W., Fornwald J., Brawner M. Wetzel R. (1996) Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide Aβ. Biochemistry 35, 7123 7130.
9. Cheng Y., Feng Z., Zhang Q.-Z. Zhang J.-T. (2006) Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol. Sin. 27, 129 139.
10. Chromy B. A., Nowak R. J., Lambert M. P. et al. (2003) Self-assembly of Aβ1-42 into globular neurotoxins. Biochemistry 42, 12749 12760.
11. Crowther R. A. (1991) Structural aspects of pathology in Alzheimer's disease. Biochim. Biophys. Acta 1096, 1 9.
12. De Felice F. G., Valasco P. T., Lambert M. P., Viola K., Fernandez S. J., Ferreira S. T. Klein W. L. (2007) Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282, 11590 11601.
13. De Felice F. G., Wu D., Lambert M. P. et al. (2008) Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol. Aging, 29, 1334 1347.
14. Dickey C. A. Petrucelli L. (2006) Current strategies for the treatment of Alzheimer's disease and other tauopathies. Expert Opin. Ther. Targets 10, 665 676.
15. Ding T. T. Harper J. D. (1999) Analysis of amyloid-β assemblies using tapping mode atomic force microscopy under ambient conditions, in Amyloid, Prions, and Other Protein Aggregates (Wetzel R., ed Methods Enzymol. 309, 510 525.
16. Dolev I. Michaelson D. M. (2004) A nontransgenic mouse model shows inducible amyloid-β (Aβ) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc. Natl Acad. Sci. USA 101, 13909 13914.
17. Fezoui Y. Teplow D. B. (2002) Kinetic studies of amyloid β-protein fibril assembly. J. Biol. Chem. 277, 36948 36954.
18. Findeis M. A. (2000) Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization. Biochim. Biophys. Acta 1502, 76 84.
19. Ghosh A. K., Kumaragurubaran N., Hong L., Keolsh G. Tang J. (2008) Memapsin 2 (beta-secretase) inhibitors: drug development. Curr. Alzheimer Res. 5, 121 131.
20. Goldsbury C., Frey P., Olivieri V., Aebi U. Muller S. A. (2005) Multiple assembly pathways underlie amyloid-β fibril polymorphisms. J. Mol. Biol. 352, 282 298.
21. Hardy J. Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353 356.
22. Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., Teplow D. B. Selkoe D. J. (1999) Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876 8884.
23. Hong H.-S., Maezawa I., Yao N., Diaz-Avalos R., Rana S., Hua D. H., Cheng R. H., Lam K. S. Jin L.-W. (2007) Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβ oligomer-induced cytotoxicity. Brain Res. 1130, 223 234.
24. Hong H.-S., Maezawa I., Budamagunta M. et al. (2008) Candidate anti-Aβ fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol. Aging [Epub ahead of print] doi :.
25. Hoozemans J. J. M., Chafekar S. M., Baas F., Eikelenboom P. Scheper W. (2006) Always around, never the same: pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer's disease. Curr. Med. Chem. 13, 2599 2605.
26. Hua D. H., Huang X., Tamura M. et al. (2003) Syntheses and bioactivities of tricyclic pyrones. Tetrahedron 59, 4795 4803.
27. Josien H. (2002) Recent advances in the development of γ-secretase inhibitors. Curr. Opin. Drug Disc. Dev. 5, 513 525.
28. Klein W. L., Krafft G. A. Finch C. E. (2001) Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219 224.
29. Klyubin I., Betts V., Welzel A. T. et al. (2008) Amyloid β protein dimmer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28, 4231 4237.
30. Lambert M. P., Barlow A. K., Chromy B. A. et al. (1998) Diffusible, non-fibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448 6453.
31. LeVine H. III. (1997) Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1-40) amyloid fibrils. Arch. Biochem. Biophys. 342, 306 316.
32. Liu Y. Schubert D. (2006) Treating Alzheimer's disease by inactivating bioactive amyloid β peptide. Curr. Alzheimer Res. 3, 129 135.
33. 42 and change presenilin 1 conformation. Nat. Med. 10, 1065 1066.
34. Lorenzo A. Yankner B. A. (1994) β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl Acad. Sci. USA 91, 12243 12247.
35. Maezawa I., Hong H.-S., Wu H.-C. et al. (2006) A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-β oligomeric complexes. J. Neurochem. 98, 57 67.
36. Maezawa I., Hong H.-S., Liu R. et al. (2008) Congo red and thioflavin-T analogs detect Aβ oligomers. J. Neurochem. 104, 457 468.
37. Martins I. C., Kuperstein I., Wilkinson H. et al. (2008) Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27, 224 233.
38. Nilsberth C., Westlind-Danielsson A., Eckman C. B. et al. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat. Neurosci. 4, 887 893.
39. Oakley H., Cole S. L., Logan S. et al. (2006) Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129 10141.
40. Olson R. E. Marcin L. R. (2007) Secretase inhibitors and modulators for the treatment of Alzheimer's disease. Ann. Rep. Med. Chem. 42, 27 47.
41. Permanne B., Adessi C., Fraga S., Frossard M. J., Saborio G. P. Soto C. (2002) Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J. Neural Transm. Suppl. 62, 293 301.
42. Quadros A., Abdullah L., Patel N. Volmar C.-H. (2007) Relevance of COX-2 inhibitors in Alzheimer's disease. Alzheimer Dis. Res. J. 1, 13 26.
43. Selkoe D. J. (2004) Alzheimer's disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140, 627 638.
44. Shankar G. M., Li S., Mehta T. H. et al. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837 842.
45. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J. Klenk D. C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76 85.
46. Soto C., Sigurdsson E. M., Morelli L., Kumar R. A., Castano E. M. Frangione B. (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4, 822 826.
47. Talaga P. (2001) beta-Amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality? Mini Rev. Med. Chem. 1, 175 186.
48. Thomas T., Nadackal T. G. Thomas K. (2001) Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. NeuroReport 12, 3263 3267.
49. Thompson L. A., Liauw A. Y., Ramnjulu M. M. et al. (2006) Synthesis and evaluation of succinoyl-caprolactam γ-secretase inhibitors. Bioorg. Med. Chem. Lett. 16, 2357 2363.
50. Tjernberg L. O., Naslund J., Lindqvist F., Johansson J., Karlstrom A. R., Thyberg J., Terenius L. Nordstedt C. (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271, 8545 8548.
51. Van Wiggeren G. D., Bynum M. A., Ertel J. P., Jefferson S., Robotti K. M., Thrush E. P., Baney D. M. Killeen K. P. (2007) A novel optical method providing for high-sensitivity and high-throughput biomolecular interaction analysis. Sens. Actuators B 127, 341 349.
52. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J. Selkoe D. J. (2002a) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long term potentiation in vivo. Nature 416, 535 539.
53. Walsh D. M., Klyubin I., Fadeeva J. V., Rowan M. J. Selkoe D. J. (2002b) Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30, 552 557.
54. Walsh D. M., Townsend M., Podlisny M. B., Shankar G. M., Fadeeva J. V., Agnaf O. E., Hartley D. M. Selkoe D. J. (2005) Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J. Neurosci. 25, 2455 2462.
55. Wang H.-W., Pasternak J. F., Kuo H. et al. (2002) Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133 140.
56. Yang F., Lim G. P., Begum A. N. et al. (2005) Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892 5901.
57. Youm J. W., Jeon J. H., Kim H., Kim Y. H., Ko K., Joung H. Kim H. (2008) Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer's disease. Biotech. Lett. 30, 1839 1845.